CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(08): 779-785
DOI: 10.1055/s-0042-1755202
Original Article

Evaluation of the risk factors for recurrence and the development of epilepsy in patients with febrile seizure

Avaliação de fatores de risco para recorrência e desenvolvimento de epilepsia em pacientes com convulsões febris
1   University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatrics, Bursa, Turkey.
,
2   University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatric Neurology, Bursa, Turkey.
,
2   University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatric Neurology, Bursa, Turkey.
,
1   University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatrics, Bursa, Turkey.
,
1   University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatrics, Bursa, Turkey.
› Author Affiliations

Abstract

Background Although febrile seizure (FS) is generally considered benign and self-limiting, there are differences regarding the risk factors, the prognosis, and the development of epilepsy.

Objective To examine the clinical and sociodemographic characteristics of patients diagnosed with FS, and to determine the risks of recurrence and the development of epilepsy.

Methods Between 2015 and 2019, we performed a retrospective evaluation of 300 patients with FS followed for at least 24 months.

Results The first episode of FS was simple in 72.7% of the patients and complex in 27.3%, and it recurred in 40%. Age under 12 months in the first FS, complex FS, and neurodevelopmental delay were found to statistically increase the risk of recurrence (p < 0.05). A total of 7% of the patients developed epilepsy, and this rate was found to be higher in patients with neurodevelopmental delay and long-term use of antiepileptic drugs (p < 0.001). The development of epilepsy was also observed in 77.8% of the patients with abnormal electroencephalogram (EEG). Epilepsy developed more frequently in those with abnormal EEG (p<0.001).

Conclusions Neurodevelopmental delay was an important risk factor for FS recurrence and the development of epilepsy. Abnormality in the EEG is an important risk factor for the development of epilepsy. We found that the long-term prophylactic treatment did not cause decreases in the recurrence of FS nor in the development of epilepsy.

Resumo

Antecedentes Embora a convulsão febril (CF) seja geralmente considerada benigna e autolimitada, existem diferenças nos fatores de risco, prognóstico e desenvolvimento de epilepsia.

Objetivo O objetivo foi examinar as características clínicas e sociodemográficas de pacientes diagnosticados com CF e determinar os riscos de recorrência e desenvolvimento de epilepsia.

Métodos Trezentos pacientes com CF, acompanhados por pelo menos 24 meses, foram avaliados retrospectivamente entre 2015 e 2020.

Resultados A primeira CF foi simples em 72,7% dos pacientes e complexa em 27,3%. CS foi recorrente em 40% dos pacientes. Encontrou-se que a idade da primeira CF inferior a 12 meses, CF complexa e atraso no neurodesenvolvimento aumentaram estatisticamente o risco de recorrência (p < 0,05). Epilepsia se desenvolveu em 7% dos pacientes. A epilepsia foi maior em pacientes com atraso no desenvolvimento neurológico e uso prolongado de drogas antiepilépticas (p < 0,001). A epilepsia se desenvolveu em 77,8% dos pacientes com eletroencefalograma (EEG) anormal. Uma diferença estatisticamente significativa foi determinada em pacientes com EEG anormal em risco de epilepsia (p < 0,001).

Conclusões O atraso no neurodesenvolvimento foi um importante fator de risco para recorrência de CF e epilepsia. A anormalidade do EEG é um importante fator de risco para o desenvolvimento de epilepsia. O tratamento de profilaxia a longo prazo não diminuiu a recorrência de CS e o desenvolvimento de epilepsia.

Authors' Contributions

ABC, AE: participated in protocol development and primary data analysis, interpretation and writing of the first version of the manuscript, and finalized the manuscript; CH, NK, MB: collected the samples and performed the clinical part of the study. All authors have read and approved the final version of the article.




Publication History

Received: 01 June 2021

Accepted: 31 October 2021

Article published online:
17 October 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil